Takenori Kanazawa, Kazushige Kadota, et al
Drug-eluting stents (DES) have substantially reduced the revascularisation rate in de novo lesions, and outcomes have been further improved with the advent of second-generation DES. In-stent restenosis (ISR) remains a significant clinical issue after DES implantation. The treatment outcome of patients with ISR lesions is worse than that of patients with de novo lesions. It has been reported that the rate of target lesion revascularisation is about 15% and that of target vessel revascularisation about 22% one year after treatment of ISR of DES, and second-generation DES are superior to first-generation DES in the treatment of ISR of DES. We sought to evaluate predictors of recurrent restenosis after second-generation DES implantation for ISR of DES.